April 26, 2011 – Patients treated with Revlimid may be at an increased risk of developing new types of cancer according to recent clinical trials. The U.S. Food and Drug Administration (FDA) has obtained results from clinical trials on the drug Revlimid that found patients taking the medication may be at an increased risk for developing other cancers. The development of new cancers was seen more frequently in patients taking Revlimid for treatment of a cancer known as multiple myeloma. Revlimid is also commonly used to treat myelodysplastic syndrome and anemia. The drug currently has a “black box” warning regarding serious risk of birth defects when either parent uses Revlimid prior to or during conception, and during pregnancy. The boxed warning also cautions about the increased risk of blood clots. The FDA has not delayed, modified or restricted the use of Revlimid for patients who are treated with the medication under the current FDA-approved guidelines. An FDA statement informs the public of the potential risk factors and the FDA is currently investigating all claims submitted related to Revlimid to determine if further recommendations for use should be released. If you or a loved one has been taking Revlimid and developed additional types of cancers after treatment began you may be eligible to file a dangerous drug claim. A dangerous drug attorney can help you review your situation and file a report to the FDA’s MedWatch system, as well as determine if you can file a lawsuit for a dangerous drug injury.
Contacting a Dangerous Drug Attorney
At Gacovino Lake & Associates we have formed a dedicated network of personal injury lawyers to serve clients nationwide for their injury claims. Our New York office serves residents of the 5 boroughs with their auto accident, medical malpractice, defective product, premises liability, and Workers’ Compensation claims. For experienced help when filing your defective product claim, contact us today – 1-800-246-4878.
